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Neutrophil Extracellular Traps in Inflammatory Bowel Disease:
Pathogenic Mechanisms and Clinical Translation
Broc Drury, Gareth Hardisty, Robert D. Gray, and Gwo-tzer Ho
Centre for Inflammation Research, University of Edinburgh, Scotland, United KingdomAbbreviations used in this paper: AAV, antineutrophil cytoplasmic
antibody-associated vasculitis; ANCA, antineutrophil cytoplasmic
antibody; CD, Crohn’s disease; DDIT4, DNA damage inducible tran-
script 4; IBD, inflammatory bowel disease; IL, interleukin; LPS, lipo-
polysaccharide; MMP, matrix metalloprotease; MPO,
myeloperoxidase; mtDNA, mitochondrial DNA; mtNET, mitochondrial
neutrophil extracellular trap; NE, neutrophil elastase; NET, neutrophilSUMMARY
Neutrophils play a key role in gut inflammation. Our review
focuses on a distinct effector mechanism, the ability of
neutrophils to form extracellular traps as a potential path-
ogenic factor and a therapeutic target for translation in in-
flammatory bowel disease.
The Inflammatory Bowel Diseases (IBD), Ulcerative Colitis
(UC) and Crohn’s Disease (CD) are characterised by chronic
non-resolving gut mucosal inflammation involving innate
and adaptive immune responses. Neutrophils, usually
regarded as first responders in inflammation, are a key
presence in the gut mucosal inflammatory milieu in IBD.
Here, we review the role of neutrophil extracellular trap
(NET) formation as a potential effector disease mechanism.
NETs are extracellular webs of chromatin, microbicidal
proteins and oxidative enzymes that are released by neu-
trophils to contain pathogens. NETs contribute to the
pathogenesis of several immune-mediated diseases such as
systemic lupus erythematosus and rheumatoid arthritis;
and recently, as a major tissue damaging process involved
in the host response to severe acute respiratory syndrome
coronavirus 2 infection. NETs are pertinent as a defence
mechanism at the gut mucosal interphase exposed to high
levels of bacteria, viruses and fungi. On the other hand,
NETs can also potentiate and perpetuate gut inflammation.
In this review, we discuss the broad protective vs. pathogenic
roles of NETs, explanatory factors that could lead to an in-
crease in NET formation in IBD and how NETsmay contribute
to gut inflammation and IBD-related complications. Finally,
we summarise therapeutic opportunities to target NETs in




lcerative colitis (UC) and Crohn’s disease (CD) are 2extracellular trap; PAD4, peptidylarginine deiminase 4; PMA, phorbol-
12-myrisate-13-acetate; PR3, proteinase 3; RA, rheumatoid arthritis;
ROS, reactive oxygen species; SLE, systemic lupus erythematosus;
TLR, Toll-like receptor; TNF, tumor necrosis factor; UC, ulcerative
colitis.
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https://doi.org/10.1016/j.jcmgh.2021.03.002Uclinical entities that define the inflammatory bowel
diseases (IBD). Both are chronic immune-mediated condi-
tions with rapidly increasing global incidence.1 Although
displaying different clinical features, they share a non-
resolving pattern of gut mucosal inflammation. Current
therapeutic approaches are focused on inhibiting the aber-
rant gut inflammation and immune response. For example,
blocking inflammatory cytokines such as tumor necrosis
factor alpha (TNF-a) and interleukin (IL)-23, the migration
of leukocytes with anti-a4b7 integrin therapies, T cellDownloaded for Anonymous User (n/a) at The University of 
2021. For personal use only. No other uses without permissresponses with thiopurines, and downregulating general
inflammation with glucocorticoids. Notwithstanding recent
therapeutic advances in IBD, primary treatment failure is
common, and complete mucosal healing is achieved in 50%
of patients with moderate-to-severe IBD. Hence, a creative
appraisal encompassing distinct mechanistic pathways is
necessary in the design of future treatment strategies
beyond mitigating downstream inflammatory responses.2
Although prominently featured in the inflamed IBD
mucosa, the translational potential of targeting the
damaging effects of neutrophils is relatively understudied. A
notable inflammatory process driven by neutrophils is
mediated via their ability to form neutrophil extracellular
traps (NETs). NETs comprise of a scaffold of DNA laced with
histones and cytotoxic neutrophil-derived proteins and are
released by neutrophils during infection and inflammation
to contain invading microbes as a protective response.3-5
NET components are indiscriminately cytotoxic and proin-
flammatory and thus can play an active role in a wide range
of pathologies involved in autoimmunity, thrombosis, and
cancer (Figure 1).6 Here, we focus on the role of the neu-
trophils and how their ability to form NETs presents an area
for clinical translation in IBD.The Role of Neutrophils in IBD
Neutrophils are the most abundant immune cell,
constituting approximately 70% of leukocytes in human
blood and are regarded as first responders of the innate
immune system. Neutrophils are best known for their rapid
recruitment to sites of infection or tissue damage to contain
pathogens.7 Neutrophils undergo apoptosis and effer-
ocytosis upon completion of their tasks to allow theEdinburgh from ClinicalKey.com by Elsevier on May 29, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
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tissue function.8-10 Persistent activation and overexuberant
recruitment of neutrophils are common features in many
inflammatory diseases. Neutrophils produce a wide variety
of chemokines, cytokines, and leukotrienes, allowing them
to recruit and activate a broad spectrum of immune
cells.11,12 Neutrophils also directly cause tissue damage by
releasing proteases such as matrix metalloproteases and
neutrophil elastase (NE),13,14 as well as from oxidative burst
which directly disrupts cell membranes.15
Neutrophils play an important role in IBD gut inflamma-
tion. They produce high levels of reactive oxygen species
(ROS) that cause epithelial barrier damage and can activate
redox-sensitive inflammatory pathways.16 They also released
a host of proteases, proinflammatory cytokines and media-
tors such as IL-8, TNF-a, and leukotriene B4 that damage the
epithelial barrier and recruit monocytes and more neutro-
phils to the gut.17,18 Neutrophil infiltration correlates with
disease activity in IBD19-23 and is a widely used and reliable
component of UC disease scoring systems.24 Calprotectin
(s100A8/9), the most widely used biomarker in IBD, consti-
tutes up to 60% of neutrophil cytosolic proteins.25,26 In
addition, many more neutrophil-derived IBD biomarkers
have been proposed,27-29 and there are several examples of
neutrophil-targeted therapies. Although a neutrophil
response is strongly featured in UC,30 in CD, neutrophil
function may be impaired with reduced migration, superox-
ide production, and phagocytic functions.31,32 In contrast to
UC, reduced neutrophil accumulation and delayed bacterial
clearance is observed at sites of injury within the gut and
systemically in CD.33 This suggests that the development of
chronic inflammation and granuloma formation is a conse-
quence of an impaired innate immune response in CD.33,34 In
this regard, similar features are seen in chronic granuloma-
tous disease and glycogen storage disease that are charac-
terized by deficient neutrophil responses.32,35NET Formation
Brinkmann et al3 first discovered NETs upon stimulating
neutrophils with IL-8, phorbol-12-myrisate-13-acetate
(PMA), or lipopolysaccharide (LPS). NETs prevent the
spread of a range of pathogens5 by trapping them in an
environment of microbicidal components and prevent
fungal growth as has been demonstrated with Candida
albicans.4 NETs contain granule proteins, histones, cyto-
plasmic proteins, and notably, calprotectin, which is
important in antifungal defence.4 Extracellular traps are an
effective and highly conserved defence mechanism.36 They
have been reported in teleosts,37 chickens,38 crabs, and
mussels,39 and in plants as part of the root tip resistance to
fungal infection,40 and many pathogens have evolved
mechanisms to repulse41 or degrade them.42,43 Given the
proximity of the gut mucosa to the microbiota, the role of
NETs is of particular importance in IBD as an integral
component of the host defense (Figure 2).
Although interest in NETs grows, a refined consensus on
NET mechanisms and classification is lacking.44,45 From a
recent expert review,44 a few aspects are noteworthy; firstDownloaded for Anonymous User (n/a) at The University of 
2021. For personal use only. No other uses without permissNETosis does not cover all forms of NET release and the
term NET formation is preferred. Second, there are many
in vivo NET stimulants including bacteria, fungal hyphae,
cytokines, immune complexes, and activated platelets.
Third, there are 2 broad mechanistic pathways for NET
formation: late lytic, occurring 2–4 hours poststimulus,
which is most commonly induced by PMA and results in
neutrophil death, and early nonlytic, which occurs 5–60 mi-
nutes poststimulus induced by, for example, Toll-like re-
ceptors (TLRs) responding to pathogen associated molecular
patterns and not resulting in neutrophil death. However, the
mechanisms underlying NET formation differ considerably
within these general pathways, depending on stimulant.46,47
For instance, PMA-induced NET formation requires protein
kinase C activation, calcium flux, ROS, myeloperoxidase
(MPO) and NE but bacteria-derived ionophore-induced NET
formation can work independently of protein kinase C acti-
vation, ROS, MPO, or NE.46 Because NETs with a similar
makeup can be induced by very different stimuli, pinpointing
what triggers increased NET formation in a pathogenic
manner is challenging in gut inflammation and IBD. For
instance, disparate factors such as C albicans and PMA can
both stimulate the release of NETs containing calprotectin, a
known biomarker in IBD.4 However, theremay be other ways
to pinpoint stimulants. Bacterial factors (eg, N-formylated
peptides) may induce the release of different granule types
and measuring the levels of primary vs secondary granule
proteins such as the ratio ofmyeloperoxidase to lactoferrin in
IBD, may provide insights into the types of neutrophil stim-
ulants in general and therefore NET stimulants.48
NETS as a Pathological Factor in
Human Disease
As with many host protective mechanisms, the deploy-
ment of NETs can be a double-edged sword.6,49 NETs can
promote or prolong both innate and adaptive immune re-
sponses in a wide variety of diseases (Figure 1). In cystic
fibrosis, NETs directly induce IL-8 and TNF-a production by
monocyte-derived macrophages,50 and in atherosclerosis,
NETs augment IL-1b and IL-6 production by monocytes
stimulated with cholesterol crystals.51 In rheumatoid
arthritis (RA), NETs provide a scaffold for autoantibodies
against citrullinated histones,52 and in systemic lupus ery-
thematosus (SLE), NETs containing LL-37 and high-mobility
group box 1 can trigger plasmacytoid dendritic cell pro-
duction of interferon alfa.53 NETs can also facilitate throm-
bosis in vasculitis by providing a framework for platelet and
tissue factor adhesion.54 NETs augment cancer progression
by trapping and spreading cancerous cells and polarizing
neutrophils toward an immunosuppressive N2-like popu-
lation.55,56 Finally, NETs contribute to sustained proin-
flammatory cytokine production, mucous secretion, and
thrombosis in COVID-19 (coronavirus disease 2019).57,58
NETS in IBD
Increased NET Formation in IBD
To date, 8 studies (Table 1) have demonstrated an
increased presence of NETs in the inflamed gut mucosa,Edinburgh from ClinicalKey.com by Elsevier on May 29, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
Figure 1. Pathogenic processes of NETs in human diseases. Nfs, neutrophils.
2021 Neutrophil Extracellular Traps in Inflammatory Bowel Disease 323stool, or blood in IBD, 4 of which stipulate that NET abun-
dance is positively correlated with active disease.64,66,69,70
Liquid chromatography-mass spectrometry–based IBD
proteomics studies reveal an increase in key NET pro-
teins such as myeloperoxidase (MPO) and NE, both of
which are highly specific to neutrophils and involved in
chromatin decondensation during NET formation,71 as
well as increased calprotectin and cathepsin G, both of
which have been found in NETs4 in both intestinal
biopsies72 and fecal samples.73 Increased levels of
NET-associated proteins in IBD have also been demon-
strated by immunofluorescence, immunohistochemistry,
or Western blot in intestinal biopsies60,65,66,69 as well as
in the colonic mucosa of experimental colitis in mice.70
Using Western blot, these increased NET-specificDownloaded for Anonymous User (n/a) at The University of 
2021. For personal use only. No other uses without permissproteins included NE, MPO, and citrullinated histone H3,
another widely used NET biomarker,66,74 and using
immunofluorescence, NETs have been found as DNA
complexed with NE, MPO, and histones.60,65,66,69 Addi-
tionally, increased NET components have been found in
the circulation of IBD patients69,70 by capture enzyme-
linked immunosorbent assay that measured DNA bound
to MPO as a surrogate marker of a NET. Although these
findings are important, colocalization or correlation of
DNA with NET-implicated proteins is not outright evi-
dence of NET formation because DNA of any source can
bind proteins released from neutrophils through several
processes including apoptosis and degranulation, and
more rigorous qualification and quantification is sug-
gested in Box 1.Edinburgh from ClinicalKey.com by Elsevier on May 29, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
Figure 2. NETs in the
gut and IBD. Inflamed
UC gut mucosa and the
presence of NETs (coloc-
alization of MPO and
s100a9 in crypt abscesses
and subepithelium [arrow-







324 Drury et al Cellular and Molecular Gastroenterology and Hepatology Vol. 12, No. 1Is increased NET formation a shared phenomenon in UC
and CD? Several studies have reported this in both
entities,60,64,69,70,73 while others found no evidence in CD.65,66
Different experimental methods and patient cohorts may
explain some of the discrepancies. For instance, Dinallo
et al66 ruled out an increase in NETs in CD intestinal biopsies
based on the absence of increased expression of peptidy-
larginine deiminase 4 (PAD4), a nuclear citrullinating enzyme
classically believed to be essential for NET formation.
However, it has been proven that PAD4 is not required for
all forms of NET release, as shown with C albicans and
group B Streptococcus–mediated NET formation.44,46
However, as UC is typically associated with higher neutro-
phil recruitment,30,33 if true, the finding of increased NETs
in UC relative to CD is perhaps not unexpected.
Increased NET abundance is also not unique or specific
to IBD and is likely present in any situation in which there is
significant neutrophil involvement and gut microbial expo-
sure. For instance, in necrotizing enterocolitis, in which gut
barrier defense is markedly compromised by inflammation,
high levels of NETs can be found in gut tissue.75 However,Downloaded for Anonymous User (n/a) at The University of 
2021. For personal use only. No other uses without permisshigher levels of proteins associated with NETs including
MPO, NE, and calprotectin can differentiate individuals with
IBD from those with noninflammatory conditions such as
irritable bowel syndrome in fecal metaproteomic studies,73
suggesting that increased NET production in the IBD is
related to gut inflammation.Are Neutrophils in IBD More Likely to Form
NETs?
Are neutrophils in IBD more prone to forming NETs?
Several angles are noteworthy. First, the local biological
microenvironment is crucial. For instance, in diabetes, a hy-
perglycemic environment primes NET formation by upregu-
lating PAD4,76 and in SLE, circulating microparticles derived
from apoptotic cells can increase the potential for NET for-
mation.77 Serum from patients with UC and CD; and media
from ex vivo culture of inflamed UC mucosa can stimulate
higher spontaneous NET formation.64,65 This suggests the
involvement of inflammatorymediators in the circulation andEdinburgh from ClinicalKey.com by Elsevier on May 29, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
Box 1.NETs in IBD: Experimental Considerations
To achieve better clarity in future work, several experimental considerations are noteworthy.
1. Multiple characterization of NET components beyond the use of single NET markers such as PAD4 are needed. Ideal
methodology would combine the use of sandwich enzyme-linked immunosorbent assays for blood work, targeting
DNA-MPO/citH3/NE complexes,59 colocalization studies in tissue using immunohistochemistry,60 intravital micro-
scopy, and live cell imaging.61,62
2. For NET formation studies, neutrophils must be isolated with an appreciation of the ability of calcium, magnesium,
and chelators to alter NET formation capacity.44,63
3. As for stimulants, PMA should ideally only be used as a positive control44 and more physiologically relevant stimuli
such as patient sera,64 cultured medium from inflamed tissue cultures,65 and combinations of IBD relevant cytokines66
should be used.
4. Additionally, previous and current treatment regimens within patient cohorts should be stated in detail because
several widely used IBD treatments such as infliximab66,67 and mesalamine68 have been shown to directly inhibit NET
formation.
2021 Neutrophil Extracellular Traps in Inflammatory Bowel Disease 325from themucosa, but triggers by transmigrated gut microbial
components such as bacterial DNA78–80 are also likely stimuli.
Second, are there intrinsically distinct neutrophil phe-
notypes in IBD that are more prone to NET formation?
Disease-specific neutrophil subsets such as type I interferon
hyperresponsive neutrophils in SLE81 or low-density neu-
trophils, implicated in a variety of diseases82,83 that are
considered more susceptible to form NETs, have been
described. He et al64 found that neutrophils, irrespective of
whether they are obtained from UC, CD, or non-IBD subjects,
had similar NET formation capacity when stimulated with
IBD sera. Dinallo et al66 demonstrated that in vitro NET
formation capacity by active UC neutrophils is similar to
healthy controls in response to a variety of stimulants
including TNF-a, LPS, and PMA. However, 3 studies pro-
vided contrary evidence, stating that in vitro, neutrophils
from CD and UC70 or from UC alone65,69 have a primed or
intrinsically increased NET formation capacity, reported as
spontaneous65,70 or PMA induced.69
Of interest, NET-prone CD177þ neutrophils are found in
increased proportions in the blood and inflamed intestinal
mucosa of both UC and CD patients.22,84 CD177 is a glyco-
protein that is exclusively expressed on neutrophils,
neutrophilic myelocytes, and metamyelocytes. CD177 is
involved in neutrophil transmigration and is upregulated
upon acute bacterial infection.85 CD177þ neutrophils have a
higher expression of granule protein genes86 and are an
activated or primed subset in several diseases including
antineutrophil cytoplasmic antibody (ANCA)–associated
vasculitis (AAV), SLE, and asthma.87,88 In IBD, CD177þ
neutrophils have a shifted gene expression profile toward
microbial defense and release more ROS, MPO, and calpro-
tectin, and produce more NETs than CD177– neutrophils.22
Notably CD177þ neutrophils in inflamed mucosa of CD and
UC patients positively correlate with Crohn’s Disease Ac-
tivity Index and UC Mayo Score.22
Third, are there increased numbers of aged neutrophils in
IBD that are more likely to form NETs? Neutrophil lifespan
can be prolonged by growth factors, cytokines, and microbialDownloaded for Anonymous User (n/a) at The University of 
2021. For personal use only. No other uses without permissproducts during infection and inflammation.89,90 Delayed
apoptosis leads to the persistence of autoantigens in RA and
AAV,8 enhanced risk of tissue damage in acute coronary
syndromes,91 and enhanced NET formation capacity in cystic
fibrosis.50 In IBD, spontaneous neutrophil apoptosis is
delayed by IL-8 and granulocyte colony-stimulating fac-
tor.92,93 With relevance to IBD, it has been reported that a
systemic, aged, proinflammatory neutrophil population with
higher NET formation capacity, defined as a CD62Llo CXCR4hi
subset, can be driven by the gut microbiota via TLRs and
myeloid differentiation factor 88–mediated pathways in
mice.94 This population is diminished upon depletion of the
microbiota with antibiotics.94Proinflammatory actions of NETs in IBD:
Abundance vs Composition
The composition of NETs and their specific effects is a
further factor to consider above abundance alone. For
instance, in psoriasis, NETs containing proinflammatory LL-
37-DNA complexes activate plasmacytoid dendritic cells,
leading to increased interferon alfa production.49 In RA,
autoantibodies against NET components such as citrulli-
nated vimentin are found in the circulation leading to
augmentation of IL-6 and IL-8 inflammatory responses52
and in SLE, NETs are embedded with highly proin-
flammatory oxidized mitochondrial DNA (mtDNA), which
stimulates type I interferon signaling through the DNA
sensor stimulator of interferon genes.95
In 2018, Angelidou et al65 described bioactive IL-1b-
decorated NETs in UC but not in CD. These IL-1b-containing
NETs formed through an autophagy-dependent mechanism
that facilitates the extrusion of NET contents.44 Here, they
showed that IL-1b–decorated NET production was linked to
the expression of DNA damage inducible transcript 4
(DDIT4) in UC.65 DDIT4 is an important, ubiquitously
expressed stress-response mammalian target of rapamycin
inhibitor linking cellular stress to autophagy-mediated NET-
associated IL-1b responses in familial MediterraneanEdinburgh from ClinicalKey.com by Elsevier on May 29, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 1.A Summary of NET Studies in IBD
Reference Methods Key findings
Bennike et al72 Liquid chromatography-mass spectrometry
(UC ¼ 10 vs controls ¼ 10).
 NET-associated proteins increased in colonic mucosa: lacto-
ferrin, MPO, NE, calprotectin, neutrophil defensin 3—UC.
Lehmann et al73 Liquid chromatography-mass spectrometry
(UC ¼ 14, CD ¼ 11, other ¼ 29, controls ¼ 17)
 NET proteins increased in stool: NE, MPO, azurocidin, and
cathepsin G—UC/CD.
Dinallo et al66 Immunohistochemistry, immunofluorescence,
Western blot; in vitro NET induction, DSS-
induced colitis (UC ¼ 9, CD ¼ 9, controls ¼ 12).
 Increased, colocalized PAD4, NE, MPO and citrullinated his-
tone H3 expression in inflamed mucosa—UC.
 UC/control neutrophils similar NET formation capacity
in vitro—UC.
 Infliximab treatment diminishes NETs—UC.
 PAD4 inhibitor attenuates colitis—DSS induced.
Li et al69 Immunofluorescence, ELISA, in vitro NET
induction; DSS-induced colitis (UC ¼ 24,
CD ¼ 24, controls ¼ 10).
 Increased MPO-DNA complexes in blood—UC/CD.
 NET formation capacity enhanced in vitro—UC.
 Impaired NET degradation in plasma—UC/CD.
 Increased, colocalized NE and citrullinated histone H3 in
inflamed colonic mucosa—UC/CD.
 Increased NET deposition in colon, depleted by DNase I
treatment—DSS induced.
 Procoagulant activity enhanced by NETs in vitro—UC/CD.
Angelidou et al65 Immunofluorescence, Western blot; ELISA, in vitro
NET induction (UC ¼ 23, CD ¼ 11, other ¼ 15,
controls ¼ 25)
 Increased, colocalized NE and citrullinated histone H3 in bi-
opsies—UC.
 Increased MPO-DNA complexes in blood—UC.
 Sera/ex vivo culture media enhances control NET formation
in vitro—UC.
 IL-1b NETs mediated by autophagy via DDIT4/stress pathway
in vitro—UC.
Gottlieb et al60 Immunofluorescence (UC ¼ 6, CD ¼ 6, control ¼ 2)  Increased, colocalized MPO, chromatin/histones and NE in
biopsies—UC/CD.
Cao et al70 Immunofluorescence, ELISA, in vitro NET
induction, DSS colitis (UC/CD ¼ 51).
 Enhanced MPO-DNA complexes in blood—UC/CD.
 Enhanced NET formation in vitro—UC/CD.
 NETs enhance procoagulant activity in vitro—UC/CD.
 DNase I protects against DSS-induced colitis.
He et al64 In vitro NET induction (UC ¼ 28, CD ¼ 23,
controls ¼ 12)
 Sera enhanced patient/control NET formation in vitro—UC/CD.
 IgG from PR3-ANCA–positive IBD enhanced control NET
formation in vitro—UC/CD.
 DNase I treatment decreased procoagulant activity in vitro—
UC/CD.
ANCA, antineutrophil cytoplasmic antibody; CD, Crohn’s disease; DSS, dextran sulfate sodium; ELISA, enzyme-linked
immunosorbent assay; IBD, inflammatory bowel disease; MPO, myeloperoxidase; NET, neutrophil extracellular trap; PAD4,
peptidylarginine deiminase 4; PR3, proteinase 3; UC, ulcerative colitis.
326 Drury et al Cellular and Molecular Gastroenterology and Hepatology Vol. 12, No. 1fever.96 DDIT4 expression was higher in UC neutrophils and
in control neutrophils stimulated with UC colon tissue cul-
ture media.65 It was proposed that this DDIT4/NET/IL-1b
pathway may be specific to UC (not CD) as a form of IL-1b
autoinflammatory disease. Angelidou et al96 previously
described that in familial Mediterranean fever, neutrophils
undergo autophagy-mediated NET formation via the DDIT4
pathway through stress mediators such as epinephrine.
Studying the effects of similar stress mediators on NET
formation may also be relevant in UC.
ANCAs may play a role in NET-mediated IBD pathology.
ANCAs drive the development of AAV in which they target
proteinase 3 (PR3) or MPO97 and initiate neutrophil-rich
necrotizing inflammation, causing organ damage.98 In UC, the
perinuclear type, pANCA, is found in up to 80% of UC pa-
tients,99,100 with a distinct subset of UC-specific ANCAs, DNase
I–sensitive ANCAs, known for targeting only nuclear-proteinDownloaded for Anonymous User (n/a) at The University of 
2021. For personal use only. No other uses without permisscomplexes.99,101 This UC-derived DNase I–sensitive ANCA can
bind to antigens present on NETs.102 In 2016, He et al64 showed
that NET formation is amplified when neutrophils were incu-
bated with ANCA-IgG isolated from active PR3-ANCA-positive
IBD patients. In addition, Li et al69 proposed a further mecha-
nism, in which ANCAs decreased the breakdown of NETs, by
attenuating DNase I activity particularly during active IBD.
Finally, ANCAs in IBD might activate neutrophils through Fc
receptor stimulation when binding granule components such as
PR3 or MPO, which have been translocated to their outer
membrane during activation, as described with AAV.101,103Are There Proinflammatory Mitochondrial NETs
in IBD?
Another area of significant interest in NET-driven pa-
thology is the existence of NETs embedded withEdinburgh from ClinicalKey.com by Elsevier on May 29, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 2.Summary of NET-targeted Therapies in IBD and Other Diseases
Targeted NET











and symptoms in DSS-induced
colitis.116,117
Streptonigrin—Reduced colonic
inflammation, weight loss, and
diarrhea; improved histological
scoring in DSS-induced colitis.11







Prolastin, elaspol, range of
low-molecular-weight
HNE inhibitors
Elaspol—Reduced weight loss and







NET DNA Recombinant human
DNase, DNase I
DNase I—Reduced weight loss; lower
disease activity index; lower
histological score; reduced
thrombotic tendencies; reduced IL-
1b, IL-6, and TNF-a69,70
Non-IBD—good safety profile in
cystic fibrosis, moderately
efficacious124
IL-1b–decorated NETs Anakinra, rilonacept,
canakinumab
Anakinra (ongoing)—IASO phase II trial
for ASUC. Question: Does
antagonism of IL-1 signaling in
addition to intravenous corticosteroid
treatment improve outcomes in
ASUC patients?125
Various including RA, FMF, and
hyperimmunoglobulinemia D
syndrome126,127
Other approaches - Antibody-mediated targeting of NETs for macrophage degradation.128 Not only breaks down DNA but also
proinflammatory/destructive NET proteins.
- Cross-linking of NET-inhibitory receptors such as signal inhibitory receptor on leukocytes-1.129 Inhibits NETs
but preserves intracellular bacterial killing.
ANCA, antineutrophil cytoplasmic antibody; ASUC, acute severe ulcerative colitis; DSS, dextran sulfate sodium; FMF, familial
Mediterranean fever; IASO, Interleukin 1 blockade in Acute Severe Colitis; IBD, inflammatory bowel disease; IL, interleukin;
MPO, myeloperoxidase; NET, neutrophil extracellular trap; RA, rheumatoid arthritis; TNF-a, tumor necrosis factor alpha.
2021 Neutrophil Extracellular Traps in Inflammatory Bowel Disease 327mitochondrial DNA (mtNETs). This is relevant as an as-
sociation of increased mtDNA levels with active UC and CD
have been reported.104 mtNET formation has been
described as early, nonlytic, and ROS dependent and was
originally demonstrated with neutrophils primed by
granulocyte-macrophage colony-stimulating factor followed
by TLR4 or complement receptor activation.105 Here, NETs
were found to contain mitochondrial DNA and the granule
proteins NE and MPO but, interestingly, not genomic DNA.
Yousefi et al55 recently proposed mtNETs are an active,
proinflammatory, antimicrobial tool that utilize mtDNA
fragments no longer needed within the cell in combination
with granule proteins, suggesting that they are true non-
lytic NETs. Although the mechanisms remain unknown,
mtNETs are now supported by many as an alternative
form of NET release,5 although they should be carefully
differentiated from incomplete mitophagy, which can lead
to the release of oxidized nucleoids containing mitochon-
drial components following cell damage.106 Their similar-
ities with bacteria point to mitochondrial components
within mtNETs as potent inflammatory mediators107,108
and oxidized mtDNA and mtNETs have now been impli-
cated in a range of diseases, including SLE and chronic
granulomatous disease95 and in sterile injury, surgery,109
and cancer.110Downloaded for Anonymous User (n/a) at The University of 
2021. For personal use only. No other uses without permissNETs and Thrombotic Tendencies in IBD
One potential implication of increased circulating NETs
in IBD is an increased thrombotic risk. Both UC and CD
patients have an increased (3-fold) risk of thromboembolic
events compared with the general population.111 Although
abnormalities in coagulation and fibrinolytic systems such
as elevated circulating fibrinogen, prothrombin, and micro-
particles have been found, these abnormalities are insuffi-
cient to explain the increased thromboembolic risk in
IBD.111 Recently, 3 separate studies have linked NETs to
increased thrombotic tendency in IBD.64,69,70 In 2016, He
et al64 found that NETs contributed to increased coagula-
tion, which could be counteracted by DNase I. Here, they
highlighted that NET NE can inactivate tissue factor inhibi-
tor and that NETs provide a scaffold for platelet and
erythrocyte adhesion. The same group went on to demon-
strate that incubating normal platelets with NETs from
active IBD patients enhanced procoagulant activity by 32%
and the ability to support fibrin formation by 42%.70
Recently, they reported the treatment of a dextran sulfate
sodium–induced mouse colitis model with DNase I led to
lower disease activity and a decrease in prothrombotic ef-
fects.69 Intriguingly, they also found ANCA-IgG to have a
role, inducing NET formation as well as microparticle
shedding by cultured endothelial cells, which acceleratedEdinburgh from ClinicalKey.com by Elsevier on May 29, 
ion. Copyright ©2021. Elsevier Inc. All rights reserved.
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dencies in IBD is a novel area and may have similarities to
other diseases such as vasculitis.54,112Beneficial Roles of NETs in IBD
NETs have been shown to play a beneficial role in
downregulating inflammation in several conditions. In RA,
NETs can downregulate IL-6 and upregulate IL-10 secretion
in LPS-activated macrophages.113 In gout, NETs contribute
to the resolution of inflammation directly by degrading cy-
tokines and chemokines via serine proteases and when NET
formation is impaired, the propensity of monosodium urate
crystals, the trigger for gout, to activate neutrophils is
amplified.114 Proteases within NETs have been shown to be
efficient regulators of cytokine activity in vitro and in vivo
and will also play a role in regulating a large number of
cytokines in IBD.115 Finally, circulating NETs may have a
role in clearing damage-associated molecular patterns such
as transmigrated bacterial components,78–80 a mechanism
proven in murine sepsis.62 Thus, some care must be taken in
targeting NETs as a therapy in IBD.Conclusion
The knowledge of NET biology has allowed new insights
into the inflammatory processes of many diseases. Although
NET formation is a relatively unexplored area in IBD,
it presents an excellent opportunity to understand the
potential contribution of a major immune cell, the neutro-
phil, in the pathogenic and nonresolving gut inflammation
in IBD. Importantly, the development of NET-targeted
therapies in IBD can draw on lessons from other diseases
(summarized in Table 2). Targeting NETs may form a
novel treatment approach to achieving complete mucosal
healing in IBD.References
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